Processing

Please wait...

Settings

Settings

Goto Application

1. US5885965 - Anti-fungal D-amino acid histatin-based peptides

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
What is claimed is:
1. A composition for treating a fungal or bacterial infection comprising one or more peptides, wherein a peptide comprises one or more D-amino acids and has an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the glycine at position 6 is replaced by lysine, arginine or another basic amino acid;
b) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the lysine at position 8 is replaced by histidine, phenylalanine or another hydrophobic amino acid;
c) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least on of the histidines at position 4, 5 and 12 is replaced by phenylalanine, tyrosine, leucine or another hydrophobic amino acid;
d) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the lysines at positions 2 and 10 is replaced by glutamine, arginine or by another basic amino acid;
e) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the arginines at positions 3 and 9 is replaced by glutamine, lysine, or by another basic amino acid; and
f) any combination of peptides having the amino acid replacements of preceding sections a)-e) with the exception that glutamine or any other non-basic amino acid cannot simultaneously occupy positions 2, 3, 9 and 10 of the amino acid sequence.
2. A composition of claim 1 wherein the amino acid sequence of said peptide is selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113-F4 as set forth in SEQ ID NO:24;
b) the amino acid sequence of peptide 113-F5 as set forth in SEQ ID NO:25;
c) the amino acid sequence of peptide 113-F12 as set forth in SEQ ID NO:26;
d) the amino acid sequence of peptide 113-F4.5 as set forth in SEQ ID NO:27;
e) the amino acid sequence of peptide 113-F4.5.12 as set forth in SEQ ID NO:28;
f) the amino acid sequence of peptide 113-K6 as set forth in SEQ ID NO:29;
g) the amino acid sequence of peptide 113-H8 as set forth in SEQ ID NO:30;
h) the amino acid sequence of peptide 113-K6H8 as set forth in SEQ ID NO:31;
i) the amino acid sequence of peptide 113-F8 as set forth in SEQ ID NO:32;
j) the amino acid sequence of peptide 113-L4.5.12 as set forth in SEQ ID NO:33;
k) the amino acid sequence of peptide 113-Y4.5.12 as set forth in SEQ ID NO:34;
l) the amino acid sequence of peptide 113-Q2.10 as set forth in SEQ ID NO:35; and
m) the amino acid sequence of peptide 113-Q3.9 as set forth in SEQ ID NO:36.
3. A composition of claim 1 wherein the peptide has a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide.
4. A composition of claim 3 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
5. A peptide comprising one or more D-amino acids and having an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the glycine at position 6 is replaced by lysine, arginine or another basic amino acid;
b) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the lysine at position 8 is replaced by histidine, phenylalanine or another hydrophobic amino acid;
c) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the histidines at position 4, 5 and 12 is replaced by phenylalanine, tyrosine, leucine or another hydrophobic amino acid;
d) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the lysines at positions 2 and 10 is replaced by glutamine, arginine or by another basic amino acid;
e) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the arginines at positions 3 and 9 is replaced by glutamine, lysine, or by another basic amino acid.
6. The peptide of claim 5 selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113-F4 as set forth in SEQ ID NO:24;
b) the amino acid sequence of peptide 113-F5 as set forth in SEQ ID NO:25;
c) the amino acid sequence of peptide 113-F 12 as set forth in SEQ ID NO:26;
d) the amino acid sequence of peptide 113-F4.5 as set forth in SEQ ID NO:27;
e) the amino acid sequence of peptide 113-F4.5.12 as set forth in SEQ ID NO:28;
f) the amino acid sequence of peptide 113-K6 as set forth in SEQ ID NO:29;
g) the amino acid sequence of peptide 113-H8 as set forth in SEQ ID NO:30;
h) the amino acid sequence of peptide 113-K6H8 as set forth in SEQ ID NO:31;
i) the amino acid sequence of peptide 113-F8 as set forth in SEQ ID NO:32;
j) the amino acid sequence of peptide 113-L4.5.12 as set forth in SEQ ID NO:33;
k) the amino acid sequence of peptide 113-Y4.5.12 as set forth in SEQ ID NO:34;
l) the amino acid sequence of peptide 113-Q2.10 as set forth in SEQ ID NO:35;
m) the amino acid sequence of peptide 113-Q3.9 as set forth in SEQ ID NO:36; and
n) the amino acid sequence of peptide 113-Q2.3.9.10 as set forth in SEQ ID NO:37.
7. The peptide of claim 5 wherein the peptide has a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide.
8. A peptide of claim 7 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
9. A method for treating a fungal or bacterial infection in an individual comprising administering to said individual a therapeutically effective amount of one or more peptides, wherein a peptide comprises one or more D-amino acids and has an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the glycine at position 6 is replaced by lysine, arginine or another basic amino acid;
b) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where the lysine at position 8 is replaced by histidine, phenylalanine or another hydrophobic amino acid;
c) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least on of the histidines at position 4, 5 and 12 is replaced by phenylalanine, tyrosine, leucine or another hydrophobic amino acid;
d) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the lysines at positions 2 and 10 is replaced by glutamine, arginine or by another basic amino acid;
e) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18 where at least one of the arginines at positions 3 and 9 is replaced by glutamine, lysine, or by another basic amino acid; and
f) any combination of the peptides having amino acid replacements of preceding sections a)-e) with the exception that glutamine or any other non-basic amino acid cannot simultaneously occupy positions 2, 3, 9 and 10 of the amino acid sequence.
10. A method for treating a fungal or bacterial infection of claim 9 wherein the amino acid sequence of said one or more peptides is selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of peptide 113-F4 as set forth in SEQ ID NO:24;
b) the amino acid sequence of peptide 113-F5 as set forth in SEQ ID NO:25;
c) the amino acid sequence of peptide 113-F12 as set forth in SEQ ID NO:26 ;
d) the amino acid sequence of peptide 113-F4.5 as set forth in SEQ ID NO:27;
e) the amino acid sequence of peptide 113-F4.5.12 as set forth in SEQ ID NO:28;
f) the amino acid sequence of peptide 113-K6 as set forth in SEQ ID NO:29;
g) the amino acid sequence of peptide 113-H8 as set forth in SEQ ID NO:30;
h) the amino acid sequence of peptide 113-K6H8 as set forth in SEQ ID NO:31;
i) the amino acid sequence of peptide 113-F8 as set forth in SEQ ID NO:32;
j) the amino acid sequence of peptide 113-L4.5.12 as set forth in SEQ ID NO:33;
k) the amino acid sequence of peptide 113-Y4.5.12 as set forth in SEQ ID NO:34;
l) the amino acid sequence of peptide 113-Q2.10 as set forth in SEQ ID NO:35; and
m) the amino acid sequence of peptide 113-Q3.9 as set forth in SEQ ID NO:36.
11. A method for treating a fungal or bacterial infection of claim 9 wherein the peptide has a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide.
12. A method for treating a fungal or bacterial infection of claim 11 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
13. A method for treating a fungal or bacterial infection of claim 9 wherein said fungal or bacterial infection is selected from the group consisting of:
a) an infection of the oral cavity;
b) an infection of the vagina;
c) an infection of the urethra;
d) an infection of the ear;
e) an infection of the skin;
f) a respiratory infection;
g) a mucosal infection;
h) an ophthalmic infection; and
i) a systemic infection.
14. A method for treating a fungal or bacterial infection of claim 13 wherein the fungus or bacterium is selected from the group consisting of:
a) Candida albicans;
b) Actinomyces actinomycetencomitans;
c) Actinomyces viscosus;
d) Bacteroides forsythus;
e) Bacteriodes fragilis;
f) Bacteriodes gracilis;
g) Bacteriodes ureolyticus;
h) Campylobacter concisus;
i) Campylobacter rectus;
j) Campylobacter showae;
k) Campylobacter sputorum;
l) Capnocytophaga gingivalis;
m) Capnocytophaga ochracea;
n) Capnocytophaga sputigena;
o) Clostridium histolyticum;
p) Eikenella corrodens;
q) Eubacterium nodatum;
r) Fusobacterium nucleatum;
s) Fusobacterium periodonticum;
t) Peptostreptococcus micros;
u) Porphyromonas endodontalis;
v) Porphyromonas gingivalis;
w) Prevotella intermedia;
x) Prevotella nigrescens;
y) Propionibacterium acnes;
z) Pseudomonas aeruginosa;
aa) Selenomonas noxia;
bb) Staphylococcus aureus;
cc) Streptococcus constellatus;
dd) Streptococcus gordonii;
ee) Streptococcus intermedius;
ff) Streptococcus mutans;
gg) Streptococcus oralis;
hh) Streptococcus pneumonia;
ii) Streptococcus sanguis;
kk) Treponema denticola;
ll) Treponema pectinovorum;
mm) Treponema socranskii;
nn) Veillonella parvula; and
oo) Wolinella succinogenes.
15. A composition for treating a fungal or bacterial infection comprising one or more peptides, wherein a peptide comprises one or more D-amino acids and has a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide, wherein said peptide has an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of histatin 9 as set forth in SEQ ID NO:9;
b) the amino acid sequence of histatin 11 as set forth in SEQ ID NO:11;
c) the amino acid sequence of peptide 101 as set forth in SEQ ID NO:13;
d) the amino acid sequence of peptide 102 as set forth in SEQ ID NO:14;
e) the amino acid sequence of peptide 103 as set forth in SEQ ID NO:15;
f) the amino acid sequence of peptide 104 as set forth in SEQ ID NO:16;
g) the amino acid sequence of peptide 105 as set forth in SEQ ID NO:17;
h) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18;
i) the amino acid sequence of peptide 129 as set forth in SEQ ID NO:23;
j) the amino acid sequence of peptide 117 as set forth in SEQ ID NO:19;
k) the amino acid sequence of peptide 118 as set forth in SEQ ID NO:20;
l) the amino acid sequence of peptide 119 as set forth in SEQ ID NO:21; and
m) the amino acid sequence of peptide 120 as set forth in SEQ ID NO:22.
16. A composition of claim 15 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
17. A peptide comprising one or more D-amino acids and having a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide, wherein said peptide has an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of histatin 9 as set forth in SEQ ID NO:9;
b) the amino acid sequence of histatin 11 as set forth in SEQ ID NO:11;
c) the amino acid sequence of peptide 101 as set forth in SEQ ID NO:13;
d) the amino acid sequence of peptide 102 as set forth in SEQ ID NO:14;
e) the amino acid sequence of peptide 103 as set forth in SEQ ID NO:15;
f) the amino acid sequence of peptide 104 as set forth in SEQ ID NO:16;
g) the amino acid sequence of peptide 105 as set forth in SEQ ID NO:17;
h) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18;
i) the amino acid sequence of peptide 129 as set forth in SEQ ID NO:23;
j) the amino acid sequence of peptide 117 as set forth in SEQ ID NO:19;
k) the amino acid sequence of peptide 118 as set forth in SEQ ID NO:20;
l) the amino acid sequence of peptide 119 as set forth in SEQ ID NO:21; and
m) the amino acid sequence of peptide 120 as set forth in SEQ ID NO:22.
18. A composition of claim 17 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
19. A method for treating a fungal or bacterial infection in an individual comprising administering to said individual a therapeutically effective amount of one or more peptides wherein a peptide comprises one or more D-amino acids and has a modification comprising the addition of at least one substituent to either the N-terminus, the C-terminus, or to both the N-terminus and C-terminus of said peptide, wherein said peptide has an amino acid sequence, of at least eight amino acids, selected from the group of amino acid sequences consisting of:
a) the amino acid sequence of histatin 9 as set forth in SEQ ID NO:9;
b) the amino acid sequence of histatin 11 as set forth in SEQ ID NO:11;
c) the amino acid sequence of peptide 101 as set forth in SEQ ID NO:13;
d) the amino acid sequence of peptide 102 as set forth in SEQ ID NO:14;
e) the amino acid sequence of peptide 103 as set forth in SEQ ID NO:15;
f) the amino acid sequence of peptide 104 as set forth in SEQ ID NO:16;
g) the amino acid sequence of peptide 105 as set forth in SEQ ID NO:17;
h) the amino acid sequence of peptide 113 as set forth in SEQ ID NO:18;
i) the amino acid sequence of peptide 129 as set forth in SEQ ID NO:23;
j) the amino acid sequence of peptide 117 as set forth in SEQ ID NO:19;
k) the amino acid sequence of peptide 118 as set forth in SEQ ID NO:20;
l) the amino acid sequence of peptide 119 as set forth in SEQ ID NO:21; and
m) the amino acid sequence of peptide 120 as set forth in SEQ ID NO:22.
20. A method for treating a fungal or bacterial infection of claim 19 wherein at least one of said modifications of said peptide is selected from the group consisting of:
a) an acetyl or a carbamyl addition at the N-terminus; and
b) an amide addition at the C-terminus.
21. A method for treating a fungal of bacterial infection of claim 19 wherein said fungal or bacterial infection is selected from the group consisting of:
a) an infection of the oral cavity;
b) an infection of the vagina;
c) an infection of the urethra;
d) an infection of the ear;
e) an infection of the skin;
f) a respiratory infection;
g) a mucosal infection;
h) an ophthalmic infection; and
i) a systemic infection.
22. A method for treating a fungal or bacterial infection of claim 21 wherein the fungus or bacterium is selected from the group consisting of:
a) Candida albicans;
b) Actinomyces actinomycetemcomitans;
c) Actinomyces viscosus;
d) Bacteroides forsythus;
e) Bacteroides fragilis;
d) Bacteroides graciclis;
f) Bacteroides ureolyticus;
g) Campylobacter concisus;
h) Campylobacter rectus;
i) Campylobacter showae;
j) Campylobacter sputorum;
k) Capnocytophaga gingivalis;
I) Capnocytophaga ochracea;
m) Capnocytophaga sputigena;
n) Clostridium histolyticum;
o) Eikenella corrodens;
p) Eubacterium nodatum;
q) Fusobacterium nucleatum;
s) Fusobacterium periodonticum;
t) Peptostreptococcus micros;
u) Porphyromonas endodontalis;
v) Porphyromonas gingivalis;
w) Prevotella intermedia;
x) Prevotella nigrescens;
y) Propionobacterium acnes;
z) Pseudomonas aeruginosa;
aa) Selenomonas noxia;
bb) Staphylococcus aureus;
cc) Streptococcus constellatus;
dd) Streptococcus gordonii;
ee) Streptococcus intermedius;
ff) Streptococcus mutans;
gg) Streptococcus oralis;
hh) Streptococcus pneumonia;
ii) Streptococcus sanguis;
jj) Treponoma denticola;
kk) Treponoma pectinovorum;
ll) Treponoma socranskii;
mm) Veillonella parvula; and
nn) Wolinella succinogenes.